Advertisement

Einsatz bakterieller Impfstoffe beim Menschen

Ein Beitrag zur Verminderung der Anwendung von Antibiotika
  • Volker Öppling
Chapter

Zusammenfassung

Das Auftreten von Bakterien, die resistent gegen antibakteriell wirkende Substanzen wie Antibiotika und Chemotherapeutika sind, ist ein seit der Entdeckung der ersten Antibiotika bekanntes Phänomen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    World Health Report 1998 (WHO, Genf).Google Scholar
  2. 2.
    Christ W (1998) Entwicklungen und Trends auf dem Gebiet der Antibiotika — Gibt es neue Wirkprinzipien? ßundesgesundhbl 41: 111–116.CrossRefGoogle Scholar
  3. 3.
    Georges P (1987) Treatment and prevention of Haemophilus influenzae type b meningitis. Pediatr Infect Dis 6:787–790.CrossRefGoogle Scholar
  4. 4.
    Campos J, Garcia-Tornel S, Sanfeliu I (1984) Susceptibility studies of multiple resistant Haemophilus influenzae isolated from pediatric patients and contacts. Antimicrob Agents Chemother 25:706–709.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    von Kries R, Heinrich B, Böhm O, Windfuhr A, Helwig H (1997) Systemische Haemophilus influenzae-Erkrankungen in Deutschland: 1992–1995. Monatsschr Kinderheilkd 145: 136–143.CrossRefGoogle Scholar
  6. 6.
    Kirschner W, Koch J (1995) Durchimpfungs grade und Impfverhalten bei Kindern in West-und Ostdeutschland im Jahr 1994. Robert Koch-Institut (Hrsg) InfFo IV, pp 10-16.Google Scholar
  7. 7.
    Siedler S, von Kries R, Lütticken R, Reinert RR (1998) Nationwide Study on Systemic Pneumoccocal Infections among children in Germany 1997. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–140 ktober, Washington DC, USA, S 52.Google Scholar
  8. 8.
    Robert Koch-Institut (Hrsg) (1998) Bakterielle Meningitis in Deutschland 1997. Epidemiologisches Bulletin 12/98, pp 79-81.Google Scholar
  9. 9.
    Prevention of Pneumococcal Disease, Recommendations of the Advisory Committee on Immunization Practices (ACIP) MMWR1997;46:No.RR-8,1-24.Google Scholar
  10. 10.
    Fedson DS (1997) Clinical Practice and Public Policy For Pneumococcal Vaccination: The Case for Germany. Presented at the Paul-Ehrlich-Institut, 6. Februar 1997 Langen, Germany.Google Scholar
  11. 12.
    Butler JC, Hofmann J, Cetron MS, Elliott JA, Facklam RR, Breiman RF (1996) The continued emergence of drug-resistant Streptococcus pneumonieae in the United States: an update from the Center for Disease Control and Prevention’s Pneumococcal Sentinel Surveillance System. J Infect Dis 174: 986–993.PubMedCrossRefGoogle Scholar
  12. 13.
    Defining the Public Health Impact of Drug-Resistant Streptococcus pmeumoniae: Report of a Working Group. MMWR 1996;45:No.RR-5,1-20.Google Scholar
  13. 14.
    Klugman KP (1998) Antimicrobial Resistance. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, pp 13.Google Scholar
  14. 14a.
    Klugmann KP (1990) Pneumococcal resistance to antibiotics. Clin Microbiol Rev 3: 171–196.Google Scholar
  15. 15.
    Dagan R, Givon N, Sjkolnik L, Yagupsky P, Fraser D (1998) Coverage by 7, 9 and 11 valent Pneumococcal Conjugate Vaccines (Pnc-V) of Otitis Media (OM) Pathogens in Israel. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, p 27.Google Scholar
  16. 16.
    Finland M (1979) Pneumonia and Pneumococcal Infections with special reference to pneumococcal pneumonia. Am Rev Respir Dis 120:481–502.PubMedGoogle Scholar
  17. 17.
    Brown EJ, Hosea SW, Hammer CH (1982) A quantitative analysis of the interactions of antiprneumococcal antibody and complement in experimental pneumococcal bacteriaemia. J Clin Invest 69:85–98.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Forester HL, Jahnigen DW, LaForce FM (1987) Inefficacy of pneumococcal vaccine in a high-risk population. Am J Med 83:425–430.CrossRefGoogle Scholar
  19. 19.
    Ortquist A, Hedlund J, Burman LA, Elbel E, Höfer M, Leinonen M, Lindblad I, Sundelof B, Kalin M (1998) Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people. Lancet 351:399–403.CrossRefGoogle Scholar
  20. 20.
    Robert Koch-Institut (Hrsg) (1998) Impfempfehlungen der Ständigen Impf kommission (STIKO) am Robert-Koch-Institut. Stand: März 1998. Epidemiologisches Bulletin 15/98, (http://www.rki.de
  21. 21.
    Black S, Shinefield H, Ray P, Lewis E, Fireman B (1998) Efficacy of Heptavalent Conjugate Pneumococcal Vaccine (Wyeth Lederle) in 37 000 Infants and Children: Results of the Northern California Kaiser Permanente Trial. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, p 18.Google Scholar
  22. 22.
    Eskola J, Kilpi T, Lankinene K, Haapakoski J, Eerola M, Takala A, Kayhty H (1998) Finnish Trial of Two Pneumococcal conjugate Vaccines Against Acute Otitis Media. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, p 20.Google Scholar
  23. 23.
    Edwards KM, White S, Wandling G, Palmer P, Cullay B, Decker MD (1998) High Rates of Nasopharyngeal Colonization with Resistant Pneumococci in Infants Attending A Private Pédiatric Practice. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, 28.Google Scholar
  24. 24.
    Ungureanu V, Pana M, Gheorghe M, Vrinceanu G (1998) Study of the Sensitivity to Antimicrobial Drugs of Some Streptococcus Pneummaoniae Strains isolated from Different Pathological States. Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, p 51.Google Scholar
  25. 25.
    Hermans PWM, Sluijter M, de Groot R (1998) Frequent Horizontal Transfer of Pneumococcal Capsular Genes: A Threat fo Conjugate Vaccine Strategies? Kongreßband, Pneumoccocal Vaccines for the World 1998 Conference, 12–14 Oktober, Washington DC, USA, p 73.Google Scholar
  26. 26.
    Robert Koch-Institut (Hrsg) (1998) Kampf gegen die Tuberkulose notwendiger denn je. Epidemiologisches Bulletin 12/98, p 81.Google Scholar
  27. 27.
    Robert Koch-Institut (Hrsg) (1998) Tuberkulose-Situation in Deutschland 1997. Epidemiologisches Bulletin 16/98, pp 113-114.Google Scholar
  28. 28.
    Robert Koch-Institut (Hrsg) (1998) Zur Arzneimittelresistenz von M. tuberculosis in Deutschland. Epidemiologisches Bulletin 36/98, p 256.Google Scholar
  29. 29.
    ACIP (1988) Use of BCG Vaccines in the Control of Tuberculosis: A Joint Statement by the ACIP and the Advisory Committee for Elimination of Tuberculsosis. MMWR 37: 663–664, 669-675.Google Scholar
  30. 30.
    The role of BCG Vaccine in the Prevention and Control of Tuberculosis in the United States. MMWR July 1996.Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Volker Öppling
    • 1
  1. 1.Paul-Ehrlich-InstitutLangenDeutschland

Personalised recommendations